Indinavir-based treatment of HIV-1 infected patients: Efficacy in the central nervous system

AIDS

Volumn 13, Issue 10, 1999, Pages 1227-1232

  Martin, Claes ^a   Sönnerborg, Anders ^a   Svensson, Jan Olof ^a   Ståhle, Lars ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Blood brain barrier; Cerebrospinal fluid; Drug concentrations; HIV 1; Indinavir; Reverse transcription polymerase chain reaction

Indexed keywords

ABACAVIR; DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG TRANSPORT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BLOOD-BRAIN BARRIER; CEREBROSPINAL FLUID; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 0032788076     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199907090-00012     Document Type: Article

References (19)

1. 1. Pardridge WM. Blood-brain barrier transport of nutrients. Review. Nutr Kev 1986, 44:15-25.
2. 2. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998, 101:289-294.
3. 3. Decks SG, Volberding PA. HIV-1 protease inhibitors. Review. AIDS Clin Rev 1997-1998:145-185.
4. 4. Ståhle I, Martin C, Svensson JO, Sönnerborg A. Indinavir in cerebrospinal fluid of HIV-1-infected patients (letter). Lancet 1997, 350:1823.
5. 5. Brinkman K, Kroon F, Hugen PW, Burger DM. Therapeutic concentrations of indinavir in cerebrospinal fluid of HIV-1-infected patients [letter; comment]. AIDS 1998, 12:537.
6. 6. Gisslen M, Hagberg L, Svennerholm B, Norkrans G. HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy [letter]. AIDS 1997, 11:1194.
7. 7. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mort Week Report 1992, 41:1-19.
8. 8. Martin C, Albert J, Hansson P, Pehrsson P, Link H, Sönnerborg A. Cerebrospinal fluid mononuclear cell counts influence CSF HIV-1 RNA levels. J Acq Immune Def Syndr & Hum Retrovirol 1998, 17:214-219.
9. 9. Ståhle L. Microdialysis in pharmacokinetics. Eur J Drug Metab & Pharmacokinetics 1993, 18:89-96.
10. 10. Tibbling G, Link H, Oman S. Principles of albumin and IgG analyses in neurological disorder. Scand J Clin Lab Invest 1977, 37:385-390.
11. 11. Olsson T, Kostulas V, Link H. Improved detection of oligoclonal IgG in cerebrospinal fluid by isoelectric focusing in agarose, double-antibody peroxidase labeling, and avidin-biotin amplification. Clin Chem 1984, 30:1246-1249.
12. 12. Skolnick AA. Protease inhibitors may reverse AIDS dementia. JAMA 1998, 279:419.
13. 13. Pialoux G, Fournier S, Moulignier A, Poveda JD, Clavel F, Dupont B. Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir [letter]. AIDS 1997, 11:1302-1303.
14. 14. Vacca JP, Dorsey BD, Schleif WA, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 1994, 91:4096-4100.
15. 15. Stellbrink HJ, Eggers C, van Lunzen J, Albrecht H, Greten H. Rapid decay of HIV RNA in the cerebrospinal fluid during antiretroviral combination therapy [letter]. AIDS 1997, 11:1655-1657.
16. 16. Filippi CG, Sze G, Farber SJ, Shahmanesh M, Selwyn PA. Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy. Radiol 1998, 206:491-498.
17. 17. Budka H. Neuropathology of human immunodeficiency virus infection [Review]. Brain Pathol 1991, 1:163-175.
18. 18. Nogales-Gaete J, Syndulko K, Tourtellotte WW. Cerebrospinal fluid (CSF) analyses in HIV-1 primary neurological disease. Ital J Neurol Sci 1992, 13:667-683.
19. 19. Henriksson A, Link H, Cruz M, Stiernstedt G. Immunoglobulin abnormalities in cerebrospinal fluid and blood over the course of lymphocytic meningoradiculitis (Bannwarth's syndrome). Annal Neurol 1986, 20:337-345.